Warm Autoimmune Hemolytic Anaemia Treatment Market Report 2023

The global Warm Autoimmune Hemolytic Anaemia (WAIHA) Treatment Market was worth US$ 582.99 million in 2022 and is predicted to be worth US$ 1598 million by 2033, growing at a CAGR of 9.6% from 2023 to 2033. The increasing prevalence of autoimmune hemolytic anaemia (WAIHA), rising awareness and diagnosis rates, and the development of new and effective treatment options all contribute to the growth of the autoimmune hemolytic anaemia (WAIHA) treatment market. From 2018 to 2022, the market for autoimmune hemolytic anaemia (WAIHA) treatment grew at a CAGR of 5.4%.

The medical procedures used to manage the symptoms and underlying causes of warm autoimmune hemolytic anaemia (WAIHA) are referred to as WAIHA treatment. WAIHA is an autoimmune illness in which the immune system assaults and destroys red blood cells by mistake, resulting in anaemia.

WAIHA is typically treated with immunosuppressive medicines such as corticosteroids, which suppress the immune system and minimise red blood cell damage. Immunomodulatory medications, such as rituximab or cyclophosphamide, that target particular components of the immune system to suppress the autoimmune response, may also be used as therapies.

Blood transfusions may be performed in some circumstances to replace destroyed red blood cells and alleviate symptoms. In severe situations, a splenectomy (surgical removal of the spleen) may be required to decrease red blood cell damage.

Market Competition

Key players in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Sanofi, Incyte Corporation, Teva Pharmaceutical Industries Ltd, Momenta Pharmaceuticals, Alexion Pharmaceuticals, Inc., Immunovant, F. Hoffmann-La Roche Ltd

Key Segments Profiled in the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry Survey

Drug Class: